Home
Search:
1146 feeds
357 categories
5057 articles (<24 hours)
11 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

Science


Valid HTML 4.01 Transitional

RSS FeedsPrecigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-TTM in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
(WorldNews Health)

 
 

26 june 2019 15:08:21

 
Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-TTM in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
(WorldNews Health)
 




Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-TTM in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS) - Milestone represents the first patient dosed with Precigen`s transformative non-viral UltraCAR-T therapeutic platform that eliminates ex vivo expansion and reduces manufacturing time to fewer than two days following gene transfer GERMANTOWN, Md., June 26, 2019/PRNewswire / -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients,...
 
13 viewsCategory: Science > Medicine
 
Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
(WorldNews Health)
Henry Schein Medical Enhances Telemedicine Solution With Medpod MobileDoc 2
(WorldNews Health)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2019 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Travel Photos Nachrichten Indigonet Finances Leer Mandarijn